Healthcare Industry News: NS5A
News Release - May 18, 2012
Achillion Announces Executive PromotionNEW HAVEN, Conn., May 18, 2012 -- (Healthcare Sales & Marketing Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN ), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Gautam Shah, Ph.D. to Executive Vice President. Dr. Shah maintains his position as Chief Compliance Officer; he had previously served as Senior Vice President.
"Since Gautam joined us in 2004, his expertise and experience have greatly facilitated all of the development programs at Achillion. Aided by the strong working relationships he has cultivated with the regulatory agencies, his tenure has been marked by significant accomplishments including regulatory submissions for all four of our clinical HCV programs and advancements in the formulation and manufacturing of our compounds," commented Michael D. Kishbauch, President and Chief Executive Officer of Achillion. "We congratulate Gautam on this well-deserved recognition and look forward to his continued regulatory oversight as our therapeutic portfolio advances through clinical development and toward the goal of establishing our protease and NS5A inhibitors as an all-oral, interferon-free treatment regimen for HCV."
The hepatitis C virus is the most common cause of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 170 million people are infected with HCV worldwide including more than 5 million people in the United States, more than twice as widespread as HIV. Three-fourths of the global HCV patient population is undiagnosed; it is a silent epidemic and a major global health threat. Chronic hepatitis, if left untreated, can lead to permanent liver damage that can result in the development of liver cancer, liver failure or death. Few therapeutic options currently exist for the treatment of HCV infection. The current standard of care is limited by its specificity for certain types of HCV, significant side-effect profile, and injectable route of administration.
About Achillion Pharmaceuticals
Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease including HCV and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated by such forward-looking statements, including statements with respect to: Achillion's expectations with respect to the future benefits to be derived from Dr. Shah's service as an executive vice president and Achillion's ability to advance a potentially best-in-class all-oral, interferon-free combination of ACH-1625 and ACH-3102. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are risks relating to, among other things Achillion's ability to: replicate in later clinical trials positive results found in earlier stage preclinical studies and clinical trials of ACH-1625 and ACH-3102; advance the development of its drug candidates under the timelines it anticipates in current and future clinical trials; obtain necessary regulatory approvals; obtain patent protection for its drug candidates and the freedom to operate under third party intellectual property; establish commercial manufacturing arrangements; identify, enter into and maintain collaboration agreements with appropriate third-parties; compete successfully with other companies that are seeking to develop improved therapies for the treatment of HCV; manage expenses; retain key employees; and raise the substantial additional capital needed to achieve its business objectives. These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and its subsequent SEC filings.
In addition, any forward-looking statement in this press release represents Achillion's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Achillion disclaims any obligation to update any forward-looking statement, except as required by applicable law.
Source: Achillion Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.